Bryan Bienvenu, MD
Hematology & Oncology · Baton Rouge, LANPI 1932121795
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,199, more than ten times the $111 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 118 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$383
- AstraZeneca$310
- Bristol Myers Squibb$258
- AbbVie$163
- Pfizer$140
- Novartis$137
- plus $939 from 27 others
Across 15 payments — averaging $2629.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$25K
- Merck$14K
What the payments were for
- Food & beverage$2,18094%
- Education$1506%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 14 | $383 |
| AstraZeneca | 13 | $310 |
| Bristol Myers Squibb | 15 | $258 |
| AbbVie | 8 | $163 |
| Pfizer | 7 | $140 |
| Novartis | 7 | $137 |
| Array Biopharma Inc | 8 | $122 |
| Exelixis Inc. | 5 | $99 |
| Merck | 7 | $98 |
| Johnson & Johnson | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Adaptive Biotechnologies Corporation | 2 | $43 |
| Sanofi | 2 | $34 |
| Deciphera Pharmaceuticals Inc. | 2 | $32 |
| Gilead | 2 | $30 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Amgen | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Acrotech Biopharma Inc. | 1 | $19 |
| CTI Biopharma Corp. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Beigene USA, Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Seagen Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$2,331 in reported general payments places this provider in the 30th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 73 | $959,332 |
| RevlimidLenalidomide | 28 | $484,360 |
| AyvakitAvapritinib | 12 | $468,549 |
| BrukinsaZanubrutinib | 28 | $415,422 |
| LenvimaLenvatinib Mesylate | 15 | $357,735 |
| Lenalidomide | 26 | $351,915 |
| CabometyxCabozantinib S-Malate | 14 | $335,326 |
| JakafiRuxolitinib Phosphate | 20 | $320,865 |
| InlytaAxitinib | 14 | $278,188 |
| Abiraterone Acetate | 62 | $257,090 |
| TasignaNilotinib Hcl | 13 | $147,036 |
| KrazatiAdagrasib | 11 | $92,846 |
| EliquisApixaban | 114 | $70,546 |
| XareltoRivaroxaban | 56 | $36,302 |
| Imatinib Mesylate | 15 | $13,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $18 | $959,33273 claims |
| Bristol Myers SquibbRevlimid | $258 | $484,36028 claims |
| Beigene USA, Inc.Brukinsa | $16 | $415,42228 claims |
| PfizerInlyta, Eliquis, Prempro, Premarin | $140 | $353,891150 claims |
| Exelixis Inc.Cabometyx | $99 | $335,32614 claims |
| Incyte CorporationJakafi | $15 | $320,86520 claims |
| NovartisTasigna, Entresto | $137 | $151,27525 claims |
| Johnson & JohnsonXarelto | $73 | $36,30256 claims |
| AbbVieSavella | $163 | $2,61512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$2M
- Nakhle SabaBaton Rouge$842K
- Sanjay JunejaBaton Rouge$346K
- Andrew DalovisioBaton Rouge$128K
- Greg BizetteBaton Rouge$32K
- Marshall StaggBaton Rouge$19K
- Christopher McCanlessBaton Rouge$18K
- Georgios ConstantinouBaton Rouge$15K
- Lauren JunejaBaton Rouge$14K
- Victor LinBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.